Skip to main content
Login
Contact
Subscribe
Search form
Search
The Observer News Enterprise
Home
Forms
News
Sports
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Classifieds
Photos
Videos
Games
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Acer Therapeutics Inc
(NQ:
ACER
)
3.020
USD
-0.050 (-1.63%)
Official Closing Price
Updated: 7:57 PM EDT, Apr 9, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Acer Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
March 29, 2021
From
GlobeNewswire News Releases
Notice of Settlement of Derivative Suits
March 25, 2021
From
GlobeNewswire News Releases
Thinking about buying stock in Acer Therapeutics, Cemtrex, Comstock Mining, Marker Therapeutics, or Strongbridge Biopharma?
March 22, 2021
InvestorsObserver issues critical PriceWatch Alerts for ACER, CETX, LODE, MRKR, and SBBP.
From
PR Newswire
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Diseas
March 22, 2021
From
GlobeNewswire News Releases
Thinking about buying stock in Check Cap, Shaw Comm., Acer Therapeutics, Intec Pharma, or GenMark Diagnostics?
March 15, 2021
InvestorsObserver issues critical PriceWatch Alerts for CHEK, SJR, ACER, NTEC, and GNMK.
From
PR Newswire
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 01, 2021
From
GlobeNewswire News Releases
Acer Therapeutics to Participate in March Virtual Investor Conferences
March 01, 2021
From
GlobeNewswire News Releases
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
February 11, 2021
Targeting a pre-NDA meeting with FDA in Q2 2021
From
GlobeNewswire News Releases
Thinking about buying stock in Acer Therapeutics, Zomedica, Novan, Atossa Therapeutics, or Tellurian?
January 25, 2021
InvestorsObserver issues critical PriceWatch Alerts for ACER, ZOM, NOVN, ATOS, and TELL.
From
PR Newswire
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for t
January 25, 2021
From
GlobeNewswire News Releases
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for t
January 25, 2021
From
ACCESSWIRE
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
December 22, 2020
Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021
From
GlobeNewswire News Releases
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden
December 17, 2020
Authors report that celiprolol may have a protective effect in COL3A1-positive vEDS patients
From
GlobeNewswire News Releases
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020
From
GlobeNewswire News Releases
SHAREHOLDER ALERT: Schubert Firm Investigating Possible Breaches of Fiduciary Duty by Acer Therapeutics Inc. Officers and Directors
October 15, 2020
Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Acer Therapeutics Inc. (NYSE: ACER) related to the company's statements about its...
From
PR Newswire
ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
October 02, 2020
ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc.
From
Business Wire News Releases
Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital
October 01, 2020
From
GlobeNewswire News Releases
NASDAQ: ACER Shareholder Notice: Update in Lawsuit Against Acer Therapeutics Inc.
September 18, 2020
San Diego, CA -- (SBWIRE) -- 09/18/2020 -- A lawsuit is pending for certain investors in Acer Therapeutics Inc. (NASDAQ: ACER) shares and NASDAQ: ACER stockholders should contact the Shareholders...
From
SBWire - Latest Press Releases
Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
August 25, 2020
From
GlobeNewswire News Releases
Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 13, 2020
From
GlobeNewswire News Releases
Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss
July 27, 2020
Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action. Acer Therapeutics is a pharmaceutical company...
From
Business Wire News Releases
Acer Therapeutics Investors Who Have Held Their Stock Continuously Since at Least September 25, 2017 Are Encouraged to Contact Kehoe Law Firm, P.C.
July 23, 2020
From
GlobeNewswire News Releases
Lifshitz Law Firm, P.C. Announces Investigation of Acer Therapeutics, Inc. (ACER), Advanced Disposal Services, Inc. (ADSW), Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunom
July 09, 2020
From
PR Newswire
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)
July 09, 2020
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets,...
From
Business Wire News Releases
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
July 08, 2020
From
GlobeNewswire News Releases
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)
June 24, 2020
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (“Acer” or the “Company”) (NASDAQ: ACER) concerning whether the board...
From
Business Wire News Releases
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020
Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital
From
GlobeNewswire News Releases
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
May 11, 2020
From
GlobeNewswire News Releases
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital
April 30, 2020
From
GlobeNewswire News Releases
Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs
March 18, 2020
Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.